Does the media refer more to UTHR or TVTX?

In the previous week, United Therapeutics had 10 more articles in the media than Travere Therapeutics. MarketBeat recorded 24 mentions for United Therapeutics and 14 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.22 beat United Therapeutics' score of 0.46 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GMAB or TVTX?

In the previous week, Travere Therapeutics had 11 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Travere Therapeutics and 3 mentions for Genmab A/S. Travere Therapeutics' average media sentiment score of 1.22 beat Genmab A/S's score of 0.86 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BBIO or TVTX?

In the previous week, BridgeBio Pharma had 28 more articles in the media than Travere Therapeutics. MarketBeat recorded 42 mentions for BridgeBio Pharma and 14 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.22 beat BridgeBio Pharma's score of 0.49 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 9 Very Positive mention(s) 8 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or TVTX?

In the previous week, Travere Therapeutics had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 14 mentions for Travere Therapeutics and 12 mentions for Ascendis Pharma A/S. Travere Therapeutics' average media sentiment score of 1.22 beat Ascendis Pharma A/S's score of 0.17 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TVTX or EXEL?

In the previous week, Travere Therapeutics had 2 more articles in the media than Exelixis. MarketBeat recorded 14 mentions for Travere Therapeutics and 12 mentions for Exelixis. Travere Therapeutics' average media sentiment score of 1.22 beat Exelixis' score of 0.80 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Travere Therapeutics (TVTX) Competitors

$62.14 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$61.31 -0.83 (-1.34%)

As of 08/14/2026 07:36 PM Eastern

Compare

TVTX vs. UTHR, GMAB, BBIO, ASND, and EXEL

Should you buy Travere Therapeutics stock or one of its competitors? Travere Therapeutics's main competitors and comparable companies include United Therapeutics (UTHR), Genmab A/S (GMAB), BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), and Exelixis (EXEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Travere Therapeutics compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

94.1% of United Therapeutics shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

United Therapeutics has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.15B	6.79	$1.33B	$27.95	17.88
Travere Therapeutics	$490.73M	11.94	-$25.55M	-$0.46	N/A

United Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

United Therapeutics has a net margin of 41.56% compared to Travere Therapeutics' net margin of -7.35%. United Therapeutics' return on equity of 20.18% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

In the previous week, United Therapeutics had 10 more articles in the media than Travere Therapeutics. MarketBeat recorded 24 mentions for United Therapeutics and 14 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.22 beat United Therapeutics' score of 0.46 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics presently has a consensus target price of $646.00, indicating a potential upside of 29.27%. Travere Therapeutics has a consensus target price of $61.67, indicating a potential downside of 0.76%. Given United Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe United Therapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

United Therapeutics beats Travere Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Travere Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Genmab A/S has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Genmab A/S has a net margin of 19.08% compared to Travere Therapeutics' net margin of -7.35%. Genmab A/S's return on equity of 14.89% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Genmab A/S presently has a consensus price target of $39.50, suggesting a potential upside of 23.67%. Travere Therapeutics has a consensus price target of $61.67, suggesting a potential downside of 0.76%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities research analysts clearly believe Genmab A/S is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Travere Therapeutics had 11 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Travere Therapeutics and 3 mentions for Genmab A/S. Travere Therapeutics' average media sentiment score of 1.22 beat Genmab A/S's score of 0.86 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.35	$963M	$1.27	25.15
Travere Therapeutics	$490.73M	11.94	-$25.55M	-$0.46	N/A

Summary

Genmab A/S beats Travere Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Travere Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Travere Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Travere Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	31.09	-$724.93M	-$3.57	N/A
Travere Therapeutics	$490.73M	11.94	-$25.55M	-$0.46	N/A

BridgeBio Pharma has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

BridgeBio Pharma currently has a consensus target price of $100.79, suggesting a potential upside of 26.21%. Travere Therapeutics has a consensus target price of $61.67, suggesting a potential downside of 0.76%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe BridgeBio Pharma is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Travere Therapeutics has a net margin of -7.35% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

In the previous week, BridgeBio Pharma had 28 more articles in the media than Travere Therapeutics. MarketBeat recorded 42 mentions for BridgeBio Pharma and 14 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.22 beat BridgeBio Pharma's score of 0.49 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	9 Very Positive mention(s)	8 Positive mention(s)	13 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BridgeBio Pharma beats Travere Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Ascendis Pharma A/S presently has a consensus price target of $299.24, suggesting a potential upside of 20.42%. Travere Therapeutics has a consensus price target of $61.67, suggesting a potential downside of 0.76%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, research analysts plainly believe Ascendis Pharma A/S is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.06
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Ascendis Pharma A/S has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Ascendis Pharma A/S has a net margin of 70.99% compared to Travere Therapeutics' net margin of -7.35%. Ascendis Pharma A/S's return on equity of 32.54% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

In the previous week, Travere Therapeutics had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 14 mentions for Travere Therapeutics and 12 mentions for Ascendis Pharma A/S. Travere Therapeutics' average media sentiment score of 1.22 beat Ascendis Pharma A/S's score of 0.17 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Travere Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$1.05B	14.80	-$258M	$12.89	19.28
Travere Therapeutics	$490.73M	11.94	-$25.55M	-$0.46	N/A

Summary

Ascendis Pharma A/S beats Travere Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Travere Therapeutics compare to Exelixis?

Travere Therapeutics (NASDAQ:TVTX) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Travere Therapeutics presently has a consensus target price of $61.67, indicating a potential downside of 0.76%. Exelixis has a consensus target price of $49.79, indicating a potential downside of 2.84%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Travere Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Exelixis	2 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.32

Exelixis has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	11.94	-$25.55M	-$0.46	N/A
Exelixis	$2.32B	5.47	$782.57M	$3.18	16.11

Travere Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Exelixis has a net margin of 35.33% compared to Travere Therapeutics' net margin of -7.35%. Exelixis' return on equity of 42.17% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
Exelixis	35.33%	42.17%	31.76%

In the previous week, Travere Therapeutics had 2 more articles in the media than Exelixis. MarketBeat recorded 14 mentions for Travere Therapeutics and 12 mentions for Exelixis. Travere Therapeutics' average media sentiment score of 1.22 beat Exelixis' score of 0.80 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.3% of Exelixis shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Exelixis beats Travere Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Travere Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVTX vs. The Competition

Export

Metric	Travere Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.86B	$3.73B	$6.99B	$13.04B
Dividend Yield	N/A	3.68%	2.56%	10.42%
P/E Ratio	-135.08	11.41	271.55	25.35
Price / Sales	11.94	1,306.95	603.87	97.86
Price / Cash	171.59	45.11	28.87	38.43
Price / Book	48.55	17.65	11.24	6.52
Net Income	-$25.55M	-$13.18M	$3.45B	$346.81M
7 Day Performance	2.05%	1.28%	0.96%	1.26%
1 Month Performance	9.58%	2.62%	2.31%	2.56%
1 Year Performance	230.18%	54.27%	62.37%	20.83%

Travere Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVTX Travere Therapeutics	1.7743 of 5 stars	$62.14 flat	$61.67 -0.8%	+230.2%	$5.86B	$490.73M	N/A	460
UTHR United Therapeutics	4.0611 of 5 stars	$529.56 -1.7%	$646.00 +22.0%	+59.6%	$22.71B	$3.18B	18.94	1,400	Analyst Revision
GMAB Genmab A/S	4.2511 of 5 stars	$30.64 -2.0%	$39.50 +28.9%	+37.0%	$19.11B	$3.72B	24.13	3,029
BBIO BridgeBio Pharma	3.5486 of 5 stars	$85.07 +0.7%	$97.33 +14.4%	+55.6%	$16.60B	$502.08M	N/A	400	Trending News Earnings Report
ASND Ascendis Pharma A/S	4.4713 of 5 stars	$252.04 -1.3%	$296.12 +17.5%	+25.3%	$15.73B	$814.57M	29.09	1,189	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVTX) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Travere Therapeutics (TVTX) Competitors

TVTX vs. UTHR, GMAB, BBIO, ASND, and EXEL

How does Travere Therapeutics compare to United Therapeutics?

Summary

How does Travere Therapeutics compare to Genmab A/S?

Summary

How does Travere Therapeutics compare to BridgeBio Pharma?

Summary

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Travere Therapeutics compare to Exelixis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX vs. The Competition

Travere Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Travere Therapeutics (TVTX) Competitors

TVTX vs. UTHR, GMAB, BBIO, ASND, and EXEL

How does Travere Therapeutics compare to United Therapeutics?

Do institutionals & insiders believe in UTHR or TVTX?

Which has better earnings & valuation, UTHR or TVTX?

Which has more risk & volatility, UTHR or TVTX?

Is UTHR or TVTX more profitable?

Does the media refer more to UTHR or TVTX?

Do analysts prefer UTHR or TVTX?

Summary

How does Travere Therapeutics compare to Genmab A/S?

Do institutionals and insiders believe in GMAB or TVTX?

Which has more volatility and risk, GMAB or TVTX?

Is GMAB or TVTX more profitable?

Do analysts rate GMAB or TVTX?

Does the media favor GMAB or TVTX?

Which has higher valuation and earnings, GMAB or TVTX?

Summary

How does Travere Therapeutics compare to BridgeBio Pharma?

Do institutionals & insiders hold more shares of BBIO or TVTX?

Which has higher valuation & earnings, BBIO or TVTX?

Which has more volatility and risk, BBIO or TVTX?

Do analysts prefer BBIO or TVTX?

Is BBIO or TVTX more profitable?

Does the media favor BBIO or TVTX?

Summary

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Do analysts prefer ASND or TVTX?

Which has more risk & volatility, ASND or TVTX?

Is ASND or TVTX more profitable?

Does the media prefer ASND or TVTX?

Which has preferable valuation and earnings, ASND or TVTX?

Summary

How does Travere Therapeutics compare to Exelixis?

Do analysts recommend TVTX or EXEL?

Which has better earnings and valuation, TVTX or EXEL?

Which has more volatility and risk, TVTX or EXEL?

Is TVTX or EXEL more profitable?

Does the media refer more to TVTX or EXEL?

Do insiders and institutionals believe in TVTX or EXEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX vs. The Competition

Travere Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools